Chiral Pure 18F-FAA Synthesis for Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 18F-labeled 6-halo-L-ascorbic acid derivatives have low labeling efficiency and are not chiral pure, leading to mixed conformations and suboptimal biological properties, which limits their effectiveness as positron tracers for tumor imaging.
Innovation Solution
A two-step labeling method is used to synthesize the chiral pure L-ascorbic acid analogue (4R, 5R)[18F]FAA, involving dissolution in anhydrous acetonitrile, mixing with K2.2.2/K2CO3 and 18F, followed by heating and solvent removal, and subsequent separation using an alumina solid phase extraction column, to achieve a high yield and purity of the radioactive compound.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a conventional 18F-labeling method is used to synthesize 6-halo-L-ascorbic acid derivatives, then the labeling process can be completed, but the labeling efficiency is low (4.9-15.6%) and the labeling time is long (90 min)
Solution Approach 1:
The patent changes the chemical parameters of the labeling reaction by using a different precursor structure (compound 1 with C-O bond) and modifying reaction conditions (solvent system, temperature, catalyst), which transforms the reaction mechanism to achieve faster and more efficient 18F-labeling with improved yield and reduced time
Solution Approach 2:
The patent replaces the conventional nucleophilic substitution mechanism with an alternative reaction pathway that uses different chemical interactions (involving C-O bond cleavage and reformation), substituting the traditional mechanical approach of 18F- labeling with a novel chemical mechanism that achieves superior results
2Manufacturing precision
If conventional 18F-labeled ascorbic acid derivatives are synthesized, then the compound can be produced, but it is not chiral pure and exists as a mixture with multiple conformations, leading to suboptimal biological properties
Solution Approach 1:
The patent introduces a chiral auxiliary or uses chiral catalysts in the synthesis pathway before the final 18F-labeling step, establishing the correct chiral configuration early in the synthesis process to ensure the final product is chiral pure with consistent biological properties
Solution Approach 2:
The patent uses a chiral intermediate compound as a mediator in the synthesis pathway, which temporarily carries the chiral information through the reaction sequence and is removed or transformed in the final steps, ensuring the product achieves high chiral purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a chiral pure 18F marker with enhanced tumor uptake and imaging capabilities, particularly in thyroid and lung cancers, demonstrating improved biological properties and clinical potential.
Implementation Method 1
subsequent separation using an alumina solid phase extraction column
Data Source
AI summary
An F-18 labeled chiral pure derivative of hydroxyfuran, a preparation method and use thereof were provided. (4R, 5R)[18F]FAA provided by the present disclosure is a chiral pure radioactive compound, and three other chiral pure [18F]FAA structural formulae are also provided by the present disclosure. The present disclosure provides a chiral pure radioactive probe (4R, 5R)[18F]FAA, which shows unique tumor diagnostic efficiency and similar distribution to AA, and can be used for early diagnosis of tumors, pathological studies, assessment of disease progression, and evaluation for efficacy.